Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES
Observational
Observational Model: Cohort, Time Perspective: Prospective
Analyze the incidence of TET2 gene mutations and Validation of the prognostic potential of TET2 mutations and MPLA screening
Analyze the incidence of TET2 gene mutations in a series of MDS patients and describe the clinical status of patients carrying mutations Validation of the prognostic potential of TET2 mutations and MPLA screening on: Response rate to treatment with Epo, Lenalidomide and Azacitidine Progression Free Survival (PFS )
2 years
No
Fortunato Morabito, MD
Principal Investigator
Unità Operativa Complessa di Ematologia- Azienda Ospedaliera di Cosenza - Italy
Italy: Ethics Committee
O-MDS-PROTOCOL
NCT01291745
September 2010
September 2015
Name | Location |
---|